SBIR/STTR Research Award
An expression system for protein production in eggs
Award amount
$100,023Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ORIGEN THERAPEUTICS
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The aim of this research is to develop an
oviduct-specific expression vector for the ultimate goal of producing
pharmaceutical proteins in eggs of transgenic chickens generated by embryonic
stem (ES) cell-mediated transgenesis technology. Regulatory sequences from the
Ovalbumin (Ov) gene will be isolated from a chicken genomic library. Expression
vectors with Ov regulatory sequences will be constructed and tested in primary
tubular gland cells from the chicken oviduct. Also explored is a strategy for
quick substitution of the protein to be produced in the expression vector. The
expression vectors will be introduced into chicken ES cells to produce chimeras
which will be bred to obtain germline transmission in the Phase II study. The
expression vector developed in this study in conjunction with Origen's ES cell
technology will greatly improve the existing transgenic chicken expression
systems. The end point of this research is a truly tissue-specific and yet high
yield expression system that facilitates production of new pharmaceutical
proteins. The system is scalable, rapid and will produce proteins with minimum
expense.
PROPOSED COMMERCIAL APPLICATION:
This technology can be widely applied to large-scale protein production for therapeutic use. The protein can be specifically expressed in the oviduct and deposited into egg white. Large quantity of proteins can be easily purified from egg white. The cloning strategy employed by this system allows production of newly identified therapeutic protein such as monoclonal antibodies in a timely fashion.
Technology keywords
Not reported